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INTRODUCTION
Human respiratory syncytial virus (RSV) is a single-
stranded, negative-sense RNA virus belonging to the 
family Paramyxoviridae and the genus Pneumovirus. 
RSV is a major cause of acute respiratory infections in all 
ages of humans, but most importantly RSV causes severe 
lower respiratory infections in infants and young children, 
or immune compromised hosts and elderly persons [1-4]. 
RSV infection becomes epidemic in every winter season 
in temperate climates or in the rainy seasons in tropical 
areas [5, 6]. It is very contagious and almost all children 
are thought to be infected at least once by 2 years of age. 
RSV bronchiolitis in infants may be a risk factor for 
developing future recurrent wheezing or asthma [7, 8, 9]. 
RSV infection may shift the profile of cytokine 
production by helper T cells from T-helper type1 (Th1) to 
T-helper type2 (Th2), which makes the infected infants 
more prone to allergic states [10-12]. Thus, developing 
effective vaccines and therapies for RSV infection are 
extremely important not only for current RSV infections 
but to reduce future burden of asthma.
The host defense system against RSV infections 
must be fully understood if effective treatment strategies 
are to be developed. The human immune system against 
microbial infections consists of two major parts, i.e. innate 
immunity and adaptive immunity. The former is our first 
line of defense against microbial infections. Recent 
discoveries have established that the innate immunity 
system recognizes so called pathogen-associated 
molecular patterns (PAMPs) of invading pathogens and 
immediately reacts with them to isolate and exclude them. 
One of the important pattern recognition receptors is the 
Toll-like receptors (TLRs) which sense most microbes on 
the cell surface or in the intracellular compartment [13, 
14]. At least 10 TLR family members (TLR1 to TLR10) 
have been identified in humans. Certain TLRs including 
TLR2, TLR3, TLR4, TLR7, TLR8 and TLR9 sense 
various PAMPs of viruses and activate nuclear factor-κB 
(NF-κB) and interferon (IFN) regulatory factors, 
inducing proinflammatory cytokines and type I IFNs [15-
17].
RSV has been reported to interact with some TLRs 
and thereby activates innate immunity. TLR4 which 
recognizes the lipopolysaccharide of bacteria also senses 
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the fusion protein of RSV together with CD14 and 
produces interleukin (IL)-6, IL-8, tumor necrosis factor 
(TNF)-α, and IL-1β [18]. TLR4-deficent mice delay 
RSV clearance in the lungs, suggesting anti-RSV 
response of TLR4 [18, 19]. More recently, it has been 
reported that TLR3, the sensor of double-stranded RNA, 
mediates inflammatory cytokine and chemokine 
production in RSV-infected epithelial cells [20]. TLR3 
regulates the pulmonary immune environment in mice 
infected with RSV but viral clearance by TLR3 has not 
been identified [21].
In this study, we focused on the antiviral role of 
TLR3 against RSV infection and investigated whether 
RSV production was affected in TLR3-overexpressed 
human lung epithelial cells. The results indicate that 
TLR3 has modest ant i -RSV act ivi ty in TLR3-
overexpressed human lung epithelial cells.
Materials and methods
Cell culture and virus infection
A549 human lung epithelial cells [22] were cultured 
in Dulbecco's modified Eagle medium (Invitrogen Corp., 
Carlsbad, CA USA) with 50μg/ml gentamicin and 10% 
fetal bovine serum (FBS). HEp-2 human epithelial cells 
were obtained from Cell Resource Center for Biomedical 
Research, Institute of Development, Aging, and Cancer, 
Tohoku University and maintained in Eagle minimal 
essential medium (MEM) (Nissui, Tokyo, Japan) with 
10% FBS. These cells were cultured in a flask at 37℃ in 
5% CO2. The Long  strain of RSV [23] was propagated in 
HEp-2 cells and the cell culture supernatants were 
centrifuged, snap frozen and stored at -80℃ after 
considerable syncytia were observed. For RSV infection 
experiments, the Long strain was inoculated at a 
multiplicity of infection (MOI) of 3 and incubated for 2h, 
next the virus inoculum was removed and the cells 
washed once with phosphate-buffered saline (PBS). The 
infected cells were cultured in the medium for 12 to 24h 
and the supernatants were snap frozen at -80℃ for RSV 
titration. For IFN-β neutralization experiments, anti-IFN-
β polyclonal antibody (PBL Biomedical Laboratories, 
Piscataway, NJ USA) was added at a concentration of 
2,000U/ml after the inoculation.
Transfection and selection
For transient transfection, A549 cells were 
transfected with human TLR3-expression vector, pUNO-
hTLR3-HA (InvivoGen, San Diego, CA USA) by using 
Effectene (Qiagen, Tokyo, Japan) following the 
instruction manual. A control vector which does not 
harbor TLR3, designated pUNO-HA, was made by 
digesting pUNO-hTLR3-HA with EcoR Ⅴ (Takara, Otsu, 
Japan) which removes the majority (59.5%) of the hTLR3 
sequence and ligating the rest of the vector with T4 DNA 
ligase (New England Biolabs, Ipswich, MA USA). At 24h 
post-transfection, the cells were infected with the Long 
strain as mentioned above. To establish the stably TLR3-
overexpressed cells, A549 cells were selected in a 
medium with Blasticidin S (InvivoGen) at 10μg/ml at 48h 
post-transfection. Each Blasticidin S-resistant cell colony 
was picked up and propagated, and thereafter stored at 
-80℃ with Cell Banker 1 (Mitsubishi Chemical Medience, 
Tokyo, Japan) until use.
Flow cytometry analysis
To detect TLR3 overexpression on the cell surface, 
cells were detached from a dish with 0.5mM EDTA 
(ethylene diamine tetraacetic acid) and resuspended in 
FACS (fluorescence activated cell sorting) buffer (3% 
FBS, 0.02% sodium azide in PBS). After centrifuge, the 
cells were stained with either PE (Phycoerythrin)-labeled 
anti-human TLR3 (eBioscience, San Diego, CA USA) 
diluted at 40μg/ml with FACS buffer or PE-labeled 
mouse IgG1 (Beckman Coulter, Fullerton, CA USA) 
diluted at 100μg/ml with FACS buffer. Cytometric 
analysis was performed with a BD FACSCalibur flow 
cytometer (BD Biosciences, San Jose, CA USA). For 
detection of intracellular TLR3 overexpression, cells were 
treated with BD Cytofix/Cytoperm solution (BD 
Biosciences) before staining with PE-labeled antibodies.
Plaque assay
Serial 10-times dilutions of the cell culture 
supernatants from RSV infection experiments were 
prepared for the plaque assay. Confluent HEp-2 cells on a 
well of 24-well plate were incubated with 150μl of the 
d i l u t an t  f o r  2h ,  t hen 1ml o f  1% FBS ,  0.75% 
methylcellulose-MEM (m-MEM) was overlaid. Another 
1ml of m-MEM was added to the well 2 days later. Five 
days after the infection the cells were fixed with 10% 
formaldehyde for overnight and stained with 0.5% crystal 
violet for 1h. The plaques were counted on microscopy. 
The plaque number was represented as an average number 
of 3 wells at the same dilution.
IFN-α /β  ELISA
Human IFN-α and IFN-β concentrations in the cell 
culture supernatants were measured with Human IFN-α 
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ELISA kit (PBL Biomedical Laboratories) and Human 
IFN-β ELISA kit (PBL Biomedical Laboratories), 
respectively, following the instruction manuals. The 
absorbance at 450nm was read by Model 680 Microplate 
Reader (Bio-Rad Laboratories, Hercules, CA USA).
RNA extraction
Viral RNA was extracted from the cell culture 
supernatants by using MagExractorTM-Viral RNA 
(Toyobo, Osaka, Japan). Total RNA was extracted from 
the RSV infected cells by using MagExractorTM-RNA 
(Toyobo). The extracted total RNA was treated with 10U 
DNase I (Takara) in 40mM Tris-HCl (pH 7.5), 8mM 
MgCl2, and 5mM DTT at 37℃ for 30min. The RNA was 
purified with phenol: chloroform: isoamyl alcohol 
(25:24:1) (Invitrogen), precipitated in isopropanol, and 
stored at -80℃ for further analyses.
Real-time RT-PCR
Real-time RT-PCR (reverse transcription polymerase 
chain reaction) was done to quantify TLR3 mRNA 
expression and RSV viral load (copy numbers) by using 
TaqMan PCR system (Applied Biosystems) with TaqMan 
RNA-to-Ct 1-Step Kit (Applied Biosystems). For TLR3 
mRNA expression, multiplex real-time RT-PCR was 
employed in a 20μl mixture containing 10μl TaqMan 
RT-PCR mix, 1μl of each TLR3 and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) TaqMan Gene 
Expression Assay (Applied Biosystems), 0.6μg template 
RNA, and RNase-free water. To quantify RSV viral load, 
an RSV vector was prepared as follows: a part of the N 
protein gene (nt 1140 to 1264) of the Long strain was 
amplified by RT-PCR, the amplicon was cloned into pCR-
4-TOPO vector with TOPO TA cloning kit (Invitrogen 
Corp.), and the cloned plasmid was identified by PCR 
(polymerase chain reaction) and the N protein gene 
sequence was confirmed by the DNA sequencing. For 
RSV quantification, the N protein gene was amplified in a 
20μl mixture containing 10μl TaqMan RT-PCR mix, 10
 μM forward primer 
5'-CATCCAGCAAATACACCATCCA-3', 10μM reverse 
primer 5'-TTCTGCACATCATAATTAGGAGTATCAA-3', 
and 2.5μM probe 5'-FAM-CGGAGCACAGGAGAT-
MGB-3', either 1μl of template RNA or the serial diluted 
RSV vectors, and RNase-free water [24]. RSV copy 
numbers were calculated using a standard curve made by 
the RSV vectors. PCR was done in 7500 Real-Time PCR 
System (Applied Biosystems) in triplicate.
Statistical analysis
Statistical analysis was performed with a two-tailed, 
unpaired Student's t test. The data were expressed as mean 
± standard deviation of the mean. A value of P＜0.05 was 
considered to be significant.
Results
Transiently overexpressed TLR3 suppresses RSV 
production
To investigate the antiviral role of TLR3 on RSV 
in fec t ion ,  human TLR3 gene was t r ans ien t ly 
overexpressed in A549 cells and the cells were infected 
with RSV. The overexpression of TLR3 was identified by 
TLR3 mRNA expression by real-t ime RT-PCR. 
Expression level of TLR3 was approximately 8 times 
higher in the pUNO-hTLR3-HA vector-transfected A549 
cells compared to that in the control pUNO-HA vector-
transfected cells at 24h post-transfection (Fig. 1a). These 
cells were infected with the Long strain of RSV at a MOI 
of 3 at 24h post-transfection. RSV copy numbers in the 
cell culture supernatants were significantly lower in the 
TLR3-overexpressed cells than in the control cells at 12h 
and 24h post-infection (Fig. 1b). At 24h post-infection, in 
particular, RSV copy number of the TLR3-overexpressed 
cells was about 30% of that of the control cells. These 
data suggest that TLR3 may suppress RSV production in 
human respiratory epithelial cells.
Stable overexpressed TLR3 was detected in the 
intracellular compartment in A549 cells
To further explain the antiviral role of TLR3 against 
RSV, stable TLR3-overexpressed A549 cell clones were 
obtained by Blasticidin S selection after transfection. 
After the selection, 13 colonies of the pUNO-hTLR3-HA-
transfected A549 cells, as well as 4 colonies of the pUNO-
HA-transfected cells, were collected. Flow cytometry 
analysis showed the same level of TLR3 expression on the 
cell surface in pUNO-hTLR3-HA-transfected and pUNO-
HA-transfected cells. However three clones of pUNO-
hTLR3-HA-transfected cells demonstrated more TLR3 
expression in the intracellular compartment compared to a 
clone of pUNO-HA-transfected cells (clone A549/HA3). 
Among these three, two clones (clones A549/TLR3-HA2 
and A549/TLR3-HA8) were used for further experiments 
(Fig. 2). Exogenous TLR3 expression in pUNO-HA-
transfected cells was not detected in flow cytometry 
analysis. Thus we concluded that A549/TLR3-HA2 and 
A549/TLR3-HA8 clones stably overexpressed TLR3 in 
the intracellular compartment and used them for further 
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RSV infection experiments.
Stably overexpressed TLR3 suppresses RSV 
production
A549/TLR3-HA2 and A549/TLR3-HA8 cells as 
well as A549/HA3 control cells were infected with the 
Long strain at MOI of 3. The cell supernatants were 
collected and snap-frozen at 12, 18, and 24h post-
infection (only 24h in A549/TLR3-HA8 cells). RSV 
production was quantified at those designated times by 
plaque assay. TLR3-overexpressed cel l c lones 
significantly suppressed RSV production compared to the 
control cell clone at 18 and 24h post-infection (Fig. 3). At 
24h post-infection, in particular, RSV production was less 
than 20% in both TLR3-overexpressed cell clones 
compared to the control cell clone. These data further 
confirmed that TLR3 had suppressed RSV production in 
A549 cells.
IFN-β  has a partial role as a mediator of TLR3 
anti-RSV activity
The antiviral activity of TLR3 is reported to involve 
type I IFNs (IFN-α/β), especially IFN-β [25]. To 
elucidate whether IFN-α/β are involved in the anti-RSV 
activity of TLR3, we measured IFN-α/β production in 
the cell culture supernatants by ELISA. IFN-α was below 
minimum detection level (＜ 12.5pg/ml) up to 24h post-
RSV infection, a finding compatible with the previous 
report that RSV infection of human epithelial cells 
induced IFN-β but not IFN-α [26]. IFN-β concentration 
could be measured by ELISA post-18h of infection. 
However, in contrast to our expectation, more IFN-β was 
secreted in the supernatants of A549/HA3 cells than in 
those of A549/TLR3-HA2 and A549/TLR3-HA8 cells at 
24h post-infection (Fig. 4).
To further explain whether IFN-β mediates the anti-
RSV activity of TLR3, anti-IFN-β antibody which 
neutralizes any secreted IFN-β was added to the cell 
culture supernatants immediately after RSV inoculation. 
A concentration of 2,000U/ml of anti-IFN-β antibody 
was sufficient to neutralize IFN-β in the supernatants of 
A549 cells at 24h after RSV infection under minimum 
detection level (＜ 25pg/ml) measured by ELISA (data 
not shown). RSV production was significantly suppressed 
in A549/TLR3-HA2 cells compared to A549/HA3 cells 
without anti-IFN-β antibody at 24h post-infection, which 
was compatible with the results presented in Fig. 3 (Fig. 
5). After neutralizing IFN-β in the supernatants, RSV 
production increased significantly in both A549/HA3 and 
A549/TLR3-HA2 cells (Fig. 5), but the increase of RSV 
production in A549/TLR3-HA2 cells was much less than 
in A549/HA3 cells (Fig. 5). These data support the 
concept that secreted IFN-β in the supernatant might 
have a limited role as a mediator of anti-RSV activity by 
TLR3.
Discussion
In this study, we have shown that both transiently 
and stably overexpressed TLR3 inhibits RSV replication 
in A549 human respiratory epithelial cells. Our finding 
conflicts with that of Rudd et al. who reported that TLR3 
had no effect on RSV replication [20]. They infected 
human kidney HEK293 cells with stable TLR3 expression 
Fig.1 a TLR3 mRNA expression in transiently pUNO-
TLR3-HA vector-transfected (TLR3) or pUNO-
HA vector-transfected (control) A549 cells 
quantified by real-time RT-PCR.
 b RSV copy numbers in the supernatants of the 
control (white bar) and the TLR3 (black bar) 
A549 cells at 12h and 24h after RSV infection 
quantified at by real-time RT-PCR. The data are 
representative of three experiments. *, P＜ 0.05; 
**, P＜ 0.01
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and vector control cells with a clinical isolate of RSV A 
strain at a MOI of 0.1. They measured RSV load by 
plaque assay in both cell lines and the number of plaques 
was shown in a log scale graph. The graph shows similar 
peaks in both cell lines and it is difficult to see clear 
differences of viral repl icat ion between them. 
Additionally, they produced TLR3-suppressed A549 cells 
with small interfering RNA (siRNA) for TLR3 (TLR3i) 
and control cells with random siRNA and infected them 
with the same RSV strain at a MOI of 1. The viral loads 
(numbers of plaques) in TLR3i and control cells are 
similar on a log scale graph. In general, virus replication 
occurs exponentially and a log scale graph is used. In our 
case, the difference of viral loads between the TLR3-
overexpressed cells and controls was statistically 
significant although it was within a single digit range. 
Therefore, we showed the viral loads using a linear scale 
graph to make the difference more evident and concluded 
that TLR3 had modest anti-RSV activity.
The authors' recent review concerning the roles of 
TLRs in regulating the immune response against RSV 
Fig.3 Plaque assay to quantify RSV production in A549/
HA3 cells (white bars), A549/TLR3-HA2 cells 
(gray bars), and A549/TLR3-HA8 cells (a black 
bar) at 12h, 18h, and 24h after RSV infection. The 
number of plaques was designated as PFU (plaque 
forming units) per ml. The data are representative 
of three experiments. *, P ＜ 0.05, N.D.: not 
determined.
Fig.2 Flow cytometry analysis to detect TLR3 expression in the cytoplasm and on the cell surface of A549/TLR3-HA2 (a) 
and A549/TLR3-HA8 (b) cells. The shaded peaks indicate A549/TLR3-HA2 and A549/TLR3-HA8 cells stained 
with PE-labeled mouse IgG1, the thin line peaks do A549/HA3 control cells stained with PE-labeled anti-human 
TLR3, and the thick line peaks do A549/TLR3-HA2 and A549/TLR3-HA8 cells stained with PE-labeled anti-human 
TLR3
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suggested that differences in infectious doses and strains 
of RSV and propagation cell lines employed might 
influence study outcome [27]. Therefore, the conflicting 
results by Rudd et al. and ourselves might be explained by 
those different factors.
An antiviral role of TLR3 for another respiratory 
virus was reported by Hewson et al. [28]. They infected 
BEAS-2B human bronchial epithelial cells with 
rhinovirus (RV) with or without anti-TLR3 antibody to 
block TLR3 which are expressed on the cell surface. 
Blocking TLR3 with antibody significantly increased RV 
release into the supernatants, suggesting an antiviral role 
of TLR3 against RV.
Virus infection activates a crucial transcription 
factor, IFN regulatory factor 3 (IRF3), and IRF3 induces 
IFN-α/β. The induced IFN-α/β activate the Janus 
kinases-signal transducers and activators of the 
transcription (JAK-STAT) signal cascade and induce 
many IFN-inducible genes involving the antiviral 
responses [29, 30]. Mediators of TLR3 antiviral activity 
were postulated by Doyle et al., after experiments in 
which TLR3 activated IRF3 and it induced IFN-β which 
inhibited murine γherpes-virus 68 (MHV68) replication 
[31]. Liu et al. reported that siRNA-mediated TLR3 
knockdown inhibited IFN-β expression following RSV 
infection in A549 cells, and suggested the IFN-β is a 
mediator of TLR3 bioactivity in A549 cells infected with 
RSV [32]. Thus, we speculated that IFN-β mediates the 
antiviral activity of TLR3 against RSV infection. Our 
IFN-β  neu t ra l i za t ion exper iments ,  however, 
demonstrated that IFN-β had only a limited role as a 
mediator of TLR3 anti-RSV activity. This is supported by 
our finding that IFN-β secretion was greater in the 
control cells than in the TLR3-overexpressed cells. We 
assumed that this reflected greater production of RSV in 
the supernatants because RSV infection induces IFN-β 
not only via TLR3 but also via other sensors such as 
retinoic acid-inducible gene I [32]. This hypothesis is 
supported by the case of RV infection mentioned above 
[28]. In BEAS-2B cells, cell surface TLR3 mediated 
production of proinflammatory mediators IL-6, CXCL8, 
and CCL5 on stimulation with poly(IC) and this 
production was reduced by inhibiting TLR3 activation 
with anti-TLR3 antibody. In contrast, such mediators 
were more produced by inhibiting TLR3 activation in case 
of RV infection and the amount of RV was higher with 
TLR3 blocking. The authors explained these results that 
when TLR3 was blocked, the antiviral response via TLR3 
Fig.4 IFN-β ELISA of the cell culture supernatants of 
A549/HA3 cells (white bars), A549/TLR3-HA2 
(gray bars), and A549/TLR3-HA8 (a black bar) 
cells at 18h and 24h after RSV infection. The data 
are representative of three experiments. *, P ＜
0.05, N.D.: not determined
Fig.5 Plaque assay to quantify RSV production without 
anti-IFN-β antibody (a-IFN-β (-), white bars) or 
with anti-IFN-β antibody (a-IFN-β (+), black 
bars) in A549/HA3 and A549/TLR3-HA2 cells at 
24h after RSV infection. The number of plaques 
was designated as PFU (plaque forming units) per 
ml . The data are representa t ive of three 
experiments. *, P＜ 0.05
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剰発現細胞でも，コントロール細胞と比較して，わずかだが
有意にRSV産生が抑制された．TLR3過剰発現細胞の上
清では，ELISAにて測定した結果，インターフェロン（IFN）
-β産生量が減少していた．また，TLR3過剰発現細胞の上
清において IFN-βを中和しても，RSV量はコントロールと
同じ水準にまで増加しなかった．以上の結果から，TLR3は
弱いながら抗 RSV作用を有し，IFN-βはこの作用における
主要な媒介物質ではないと考えられた．
　ヒトRSウイルス（RSV）は乳幼児に急性細気管支炎な
どの下気道感染症をしばしば引き起こす．一方，自然免疫
のパターン認識受容体として，広範囲に病原体を認識する
Toll-like receptors（TLRs）は，感染症に対する宿主側の最
前線の防御機構である．本研究は，2本鎖RNAを認識す
るToll-like receptor 3（TLR3）の抗 RSV作用を検討する
ことを目的とした．ヒトTLR3発現プラスミドベクターを
A549細胞に導入し，TLR3を一過性または恒常的に過剰
発現させ，RSV Long株を感染させた．いずれのTLR3過
